Macrophage migration inhibitory factor: A counter-regulator of glucocorticoid action and critical mediator of septic shock

Journal of Inflammation

Volumn 47, Issue 1-2, 1995, Pages 39-51

  Calandra, Thierry ^a   Bucala, Richard ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

cytokine; glucocorticoids; macrophage; MIF; pituitary; septic shock; T cell

Indexed keywords

GLUCOCORTICOID; MACROPHAGE MIGRATION INHIBITION FACTOR;

CONFERENCE PAPER; CORTICOSTEROID THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LEUKOCYTE MIGRATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; GLUCOCORTICOIDS; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MOLECULAR SEQUENCE DATA; RECEPTORS, GLUCOCORTICOID; SHOCK, SEPTIC;

EID: 0029551304     PISSN: 10787852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Orth DN, Kovacs WJ, DeBold CR: Wilson JD, Foster DW (eds.): The adrenal cortex. In "Williams Textbook of Endocrinology." Vol. 9. 4th ed. Philadelphia: Saunders, 1992, pp. 489-619.
2. Goldstein RA, Bowen DL, Fauci AS: Gallin Jl, Goldstein IM, Snyderman R (eds.): Adrenal corticosteroids. In "Inflammation: Basic Principles and Clinical Correlates." Vol. 55. 2nd ed. New York: Raven Press, 1992, pp. 1061-1081.
3. Munck A, Guyre P-M, Holbrook N-J: Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocrinol Rev 5:25-44, 1984.
4. Bertini R, Bianchi M, Ghezzi P: Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J Exp Med 167:1708-1712,1988.
5. Zuckerman S-H, Shellhaas J, Butler L-D: Differential regulation of lipopolysaccharide-induced interleukin 1 and tumor necrosis factor synthesis: Effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunol 19:301-305, 1989.
6. Hawes A-S, Rock C-S, Keogh C-V, Lowry S-F, Galvano S-E: In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia co//endotoxin. Infect Immun 60:2641-2647, 1992.
7. Fantuzzi G, Di Santo E, Sacco S, Benigni F, Ghezzi P: Role of the hypothalamus-pituitary-adrenal axis in the regulation of TNF production in mice. J Immunol 155:3552-3555, 1995.
8. Bernhagen J, Calandra T, Mitchell R-A, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756-759, 1993.
9. Bernhagen J, Mitchell R-A, Calandra T, Voelter W, Cerami A, Bucala R: Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33:14144-14155, 1994.
10. Mitchell R, Bacher M, Bernhagen J, Pushkarskaya T, Seidin M, Bucala R: Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol 154:3863-3870, 1995.
11. George M, Vaughan J-H: In vitro cell migration as a model for delayed hypersensitivity. Proc Soc Exp Biol Med 111:514-521, 1962.
12. Bloom B-R, Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80-82, 1966.
13. David J: Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sei USA 56:72-77, 1966.
14. Nathan C-F, Remold H-G, David J-R: Characterization of a lymphocyte factor which alters macrophage function. J Exp Med 137:275-288, 1973.
15. Nathan C-F, Karnovsky M-L, David J-R: Alterations of macrophage functions by mediators from lymphocytes. J Exp Med 133:1356-1376, 1971.
16. Churchill W-H, Piessens W-F, Sulis C-A, David J-R: Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigen become cytotoxic for tumor cells. J Immunol 115:781-786, 1975.
17. Thurman G-B, Braude I-A, Gray P-W, Oldham R-K, Stevenson H-C: MIF-like activity of natural and recombinant human interferon-gamma and their neutralization by monoclonal antibody. J Immunol 134:305-309,1985.
18. Mclnnes A, Rennick D-M: Interleukin 4 induces cultured monocytes/macrophages to form giant multinucleated cells. J Exp Med 167:598-611, 1988.
19. Herriott M-J, Leu R-W: Activation of mouse macrophages for migration inhibition and for tumor cytotoxicity is mediated by interferon-gamma priming and triggering by various agents. J Interferon Res 7:165-171, 1993.
20. Weiser W-Y, Temple P-A, Witek-Gianotti J-S, Remold H-G, Clark S-C, David J-R: Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sei USA 86:7522-7526, 1989.
21. WeiserW-Y, Pozzi L-M, David J-R: Human recombinant migration inhibitory factor activates human macrophages to kill Leishmania donovani. J Immunol 147:2006-2011, 1991.
22. Weiser W-Y, Pozzi L-M, Titus R-G, David J-R: Recombinant human migration inhibitory factor has adjuvant activity. Proc Natl Acad Sei USA 89:8049-8052, 1992.
23. Orme I-M, Furney S-K, Skinner P-S, Roberts AD, Brennan PJ, Russell DG, Shiratsushi H, Ellner JJ, Weiser WY: Inhibition of growth of Mycobacterium avium in murine and human mononuclear phagocytes by migration inhibitory factor. Infect Immunol 61:338-342,1993.
24. Cunha F-Q, Weiser W-Y, David J-R, Moss D-W, Moncada S, Liew F-Y: Recombinant migration inhibitory factor induces nitric oxyde synthase in murine macrophages. J Immunol 150:1908-1912, 1993.
25. David J-R: Erratum: Important note on recombinant macrophage migration inhibition factor. J Immunol 151, 1993.
26. David J-R: Corrections, Immunology. Proc Natl Acad Sei USA 90:12056, 1993.
27. Paralkar V, Wistow G: Cloning the human gene for macrophage migration inhibitory factor (MIF). Genomics 19:48-51, 1994.
28. Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R: Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1:781-788,1995.
29. Meinhardt A, Bacher M, McFarlane J-R, Metz C-N, Seitz J, Hedger M-P, de Kretser D-M, Bucala R: Macrophage migration inhibitory factor (MIF) production by Leydig cells: Evidence for a role in the regulation of testicular function. Endocrinology (in press).
30. Sun H, Bernhagen J, Bucala R, Lolis E: Crystal structure at 2.6A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sei USA 93:5191-5196, 1996.
31. Suzuki M, Sugimoto H, Nakagawa A, Tanaka I, Nishihira J, Sakai M: Crystal structure of the macrophage migration inhibitory factor from rat liver. Nature Struct Biol 3:259-266, 1996.
32. Subramanya H-S, Roper D-l, Dauter Z, Dodson E-J, Davies G-J, Wilson KS, Wigley D-B: Enzymatic ketonization of 2-hydroxymuconate: Specificity and mechanism investigated by the crystal structures of two isomerases. Biochemistry 35:792-802, 1996.
33. Rosengren E, Bucala R, Aman P, Jacobsson L, Odh G, Metz C-N, Rorsman H: The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 2:143-149, 1996.
34. Blocki F-A, Schlievert P-M, Wackett L-P: Rat liver protein linking chemical and immunological detoxification system. Nature 360:269-270, 1992.
35. Pearson W-R: MIF proteins are not glutathione transferase homologs. Protein Sei 3:525-527, 1994.
36. Sherry B, Yarlett N, Strupp A, Cerami A: Identification of cyclophilin as a pro-inflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sei USA 89:3511-3515, 1992.
37. Schreiber S-L, Crabtree G-R: The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136-142,1002.
38. Calandra T, Bernhagen J, Metz C-N, Spiegel L-A, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced counter-regulator of cytokine production. Nature 377:68-71, 1995.
39. Calandra T, Bernhagen J, Mitchell R-A, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895-1902, 1994.
40. Bacher M, Metz C-N, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T, Bucala R: An essential regulatory role for MIF in T-cell activation. Proc Natl Acad Sei USA 93:7849-7854, 1996.
41. Bernhagen J, Bacher M, Calandra T, Metz C-N, Doty S, Donnelly T, Bucala R: An essential role for macrophage migration inhibitory factor (MIF) in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 183:277-282, 1996.
42. Tracey K-J, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ 3d, Zentella A, Albert JD, Shires T, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986.
43. Okusawa S, Gelfand J-A, Ikejima T, Connolly R-J, Dinarello C-A: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81:1162-1172, 1988.
44. Gillis S, Crabtree G-R, Smith K-A: Glucocorticoid-induced inhibition of T cell growth factor production. J Immunol 123:1624-1631, 1979.
45. Arya S-K, Wong-Staal F, Gallo R-C: Dexamethasonemediated inhibition of human T cell growth factor and gamma-interferon messenger RNA. J Immunol 133: 273-276, 1984.
46. Knudsen P-J, Dinarello C-A, Strom T-B: Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin-1 in U937 cells. J Immunol 139:4129-4134, 1987.
47. Beutler B, Krochin N, Milsark I-W, Luedke C, Cerami A: Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science 232: 977-980, 1986.
48. Lew W, Oppenheim J-J, Matsushima K: Analysis of the suppression of IL-α and IL-1α production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone. J Immunol 140:1895-1902, 1988.
49. Auphan N, DiDonato J-A, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-kB activity trough induction of IkB synthesis. Science 270:286-290, 1995.
50. Scheinman R-l, Cogswell P-C, Lofquist A-K, Baldwin A-S Jr: Role of transcriptional activation of IkBa mediation of immunosuppression by glucocorticoids. Science 270:283-286, 1995.
51. Bone R-C, Fisher C-J, Clemmer T-P, Slotman GJ, Metz ÇA, Balk RA: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658, 1987.
52. The Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659-665, 1987.